Multiple Myeloma Features Archive

General Oncology Cancer Recurrence: Tackling a Valid Survivor Fear

Cancer Recurrence: Tackling a Valid Survivor Fear

Researchers are learning that roughly half of survivors live with a moderate to high degree of fear of recurrence, and teaching techniques to better cope with uncertainty is one way to help.

Multiple Myeloma Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma

Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma

XPO1 inhibition restores the ability of intranuclear tumor suppressor genes to disrupt oncoproteins; it is emerging as a promising new investigational strategy in MM.

Multiple Myeloma Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma

Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma

The findings may support the triplet regimen as a new standard of care for these patients, according to Dr Facon.

Multiple Myeloma Results From LYRA Phase 2 Study of Frontline Multiple Myeloma Therapy

Results From LYRA Phase 2 Study of Frontline Multiple Myeloma Therapy

Habte Yimer, MD, discusses his findings at the ASH 2018 meeting.

Multiple Myeloma Phase 3 POLLUX Study: Three-Year Follow-Up

Phase 3 POLLUX Study: Three-Year Follow-Up

Nizar Bahlis, MD, discusses his findings at the ASH 2018 meeting.

Multiple Myeloma Elotuzumab Plus Pomalidomide and Dexamethasone for R/R Multiple Myeloma

Elotuzumab Plus Pomalidomide and Dexamethasone for R/R Multiple Myeloma

Sundar Jagannath, MD, discusses his findings at ASH 2018.

Multiple Myeloma ASH 2018: New Developments in Treatment of Multiple Myeloma

ASH 2018: New Developments in Treatment of Multiple Myeloma

Robert Rifkin, MD, FACP, discusses the latest research being presented at ASH 2018.

Multiple Myeloma Phase 1, 2 Study Data on Venetoclax for MM

Phase 1, 2 Study Data on Venetoclax for MM

Rod A. Humerickhouse, MD, PhD, discusses phase 1, 2 findings on venetoclax for multiple myeloma.

Multiple Myeloma Early-Access Daratumumab Trial Supports Safety in Relapsed, Refractory MM

Early-Access Daratumumab Trial Supports Safety in Relapsed, Refractory MM

Researchers also used the trial to collect more information on safety, patient‐reported outcomes, and a specific premedication treatment protocol.

General Oncology Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

General Oncology Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

General Oncology The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

Dr Vorobiof discusses the important patient factors that can be missed via standard data collection methods for those with cancer.

Multiple Myeloma Risk of Secondary Primary Malignancy Does Not Outweigh Benefit of Novel Agents for Multiple Myeloma

Risk of Secondary Primary Malignancy Does Not Outweigh Benefit of Novel Agents for Multiple Myeloma

A small study identified risk factors for SPM, but survival benefits of treatment were still determined to outweigh risk.

General Oncology Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

General Oncology Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

General Oncology Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

Lymphoma Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?

Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?

The Leukemia & Lymphoma Society partnered with Sutro Biopharma to test the safety of the investigational CD74-targeting antibody-drug conjugate STRO-001 for 2 blood cancers.

Multiple Myeloma Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma

Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma

A patient's frailty has been determined to be associated with a higher likelihood of developing toxicities, a poor therapeutic response, and decreased survival.

General Oncology Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

General Oncology Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Multiple Myeloma Precision Medicine: Personalizing Treatment for Multiple Myeloma

Precision Medicine: Personalizing Treatment for Multiple Myeloma

Targeted treatment options for patients with relapsed/refractory multiple myeloma are described.

General Oncology Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

General Oncology FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

General Oncology Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

Multiple Myeloma Selinexor and Multiple Myeloma

Selinexor and Multiple Myeloma

Early preclinical and clinical data have shown that selinexor has broad activity against multiple hematologic malignancies and notable antimyeloma activity.

General Oncology Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Multiple Myeloma Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy

Considerations for Relapsed Myeloma Should Match Patient, Disease, and Therapy

Selecting therapies for patients with multiple myeloma is challenging because the disease is inherently heterogeneous.

General Oncology Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Multiple Myeloma Bone Imaging With Improved Modalities in Multiple Myeloma

Bone Imaging With Improved Modalities in Multiple Myeloma

Bone imaging is a critical aspect of care for patients with multiple myeloma, and recent advances in imaging modalities have improved detection of lytic lesions and bone marrow involvement—but incorporating these new modalities into clinical practice has been challenging.

General Oncology Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Multiple Myeloma Value, Not Cost, Should Be Considered for Myeloma Treatment

Value, Not Cost, Should Be Considered for Myeloma Treatment

Even though cancer drugs only account for approximately 1% of the total health care spend, physicians can serve as advocates for patients struggling to afford recommended treatments.

Multiple Myeloma Global Burden of Myeloma Increasing, Access to Treatments Lacking

Global Burden of Myeloma Increasing, Access to Treatments Lacking

A new study reveals that an aging world population is the predominant contributor to a 126% increase in age-standardized incidence rates of multiple myeloma from 1990 to 2016.

General Oncology ARID1A Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

New findings bolster the case for the predictive utility of ARID1A mutations.

General Oncology Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

General Oncology Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

General Oncology Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Prostate Cancer Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Multiple Myeloma Daratumumab and Elotuzumab: Potential mAb Therapies for Multiple Myeloma

Daratumumab and Elotuzumab: Potential mAb Therapies for Multiple Myeloma

Daratumumab is moving from a monotherapy for relapsed and refractory myeloma to a potential frontline player in combination induction regimens. And on the horizon are investigational bispecific antibodies, mAb-drug conjugates, and CAR-T therapies that might offer new advances against what today remains an incurable disease.

General Oncology Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Multiple Myeloma Early Success Gives Hope for CAR T-Cell Therapy in Multiple Myeloma

Early Success Gives Hope for CAR T-Cell Therapy in Multiple Myeloma

Early trial results show that immunotherapy using chimeric antigen receptor (CAR) T-cell therapy may be effective in patients with multiple myeloma.

Multiple Myeloma Do 9/11 Firefighters Really Have A Higher Incidence of MGUS?

Do 9/11 Firefighters Really Have A Higher Incidence of MGUS?

The firefighting profession has previously been associated with a higher risk of MGUS and myeloma compared with the general population.

General Oncology The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

General Oncology HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

General Oncology Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

General Oncology Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

Phase 1 trials should be considered therapeutic options for some patients.

Side Effect Management Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

General Oncology Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

General Oncology Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

Multiple Myeloma Are African-American and Hispanic Patients With Myeloma Receiving the Best Care?

Are African-American and Hispanic Patients With Myeloma Receiving the Best Care?

Patient outcomes following the diagnosis of multiple myeloma have improved markedly over recent years, but racial and ethnic disparities exist.

General Oncology Diagnosing Medicine's Intractable Gender Pay Gap

Diagnosing Medicine's Intractable Gender Pay Gap

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.

Multiple Myeloma Should the General Population Be Screened for MGUS?

Should the General Population Be Screened for MGUS?

Still unresolved is whether to screen the general population for MGUS, a largely asymptomatic condition usually noted during routine blood testing.

Side Effect Management Managing Adverse Events in the Era of Immunotherapy

Managing Adverse Events in the Era of Immunotherapy

The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.

General Oncology Healthful Lifestyles and Cancer: Much More Than A Single Behavior

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.

General Oncology Cancer Immunosurveillance Comes of Age

Cancer Immunosurveillance Comes of Age

As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.

Multiple Myeloma Reasons for MGUS Progression to Myeloma Remain Unclear

Reasons for MGUS Progression to Myeloma Remain Unclear

Studying how MGUS and myeloma clones change over time might yield new insights into myeloma's molecular heterogeneity.

General Oncology Does Immune Checkpoint Inhibition Have A Dark Side?

Does Immune Checkpoint Inhibition Have A Dark Side?

Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.

General Oncology Cannabis for Cancer: An Uncertain Future

Cannabis for Cancer: An Uncertain Future

While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.

General Oncology Can Understanding the Gut Microbiome Improve Clinical Oncology?

Can Understanding the Gut Microbiome Improve Clinical Oncology?

Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.

Multiple Myeloma Can MDM2 Inhibition With Nutlins Indirectly Restore p53 Function?

Can MDM2 Inhibition With Nutlins Indirectly Restore p53 Function?

Disruptions of the p53 tumor suppressor pathway play a key role in tumorigenesis and tumor progression in solid and hematologic malignancies.

General Oncology Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.

Multiple Myeloma Daratumumab for Newly Diagnosed Multiple Myeloma

Daratumumab for Newly Diagnosed Multiple Myeloma

Jesus San Miguel, MD, PhD, discusses his presentation at the ASH 2017 meeting in Atlanta.

Multiple Myeloma Daratumumab Given Subcutaneously for Multiple Myeloma

Daratumumab Given Subcutaneously for Multiple Myeloma

Ajai Chari, MD, discusses his findings at the ASH 2017 meeting in Atlanta.

General Oncology Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.

Hematologic Cancers Gwen Nichols, MD, on Hematologic Cancers, Emerging Treatments, and the LLS

Gwen Nichols, MD, on Hematologic Cancers, Emerging Treatments, and the LLS

Cancer Therapy Advisor interviews Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society (LLS), about the LLS's research directions and how the treatment of hematologic malignancies is changing.

General Oncology The Warburg Effect: Can Cancer Be Starved of Sugar?

The Warburg Effect: Can Cancer Be Starved of Sugar?

A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.

Multiple Myeloma Q&A With Shaji Kumar, MD: Looking to the Future of Multiple Myeloma Treatment

Q&A With Shaji Kumar, MD: Looking to the Future of Multiple Myeloma Treatment

Cancer Therapy Advisor asked Shaji Kumar, MD, to share his thoughts about where we are now and where we are going regarding promising data and novel approaches for MM treatment.

Multiple Myeloma Alexander Lesokhin, MD, on the Potential of Immunotherapy for Myeloma

Alexander Lesokhin, MD, on the Potential of Immunotherapy for Myeloma

Cancer Therapy Advisor's Jonathan Goodman interviews Alexander Lesokhin, MD, a hematologic oncologist at Memorial Sloan Kettering Cancer Center in New York, New York, who specializes in treating patients with multiple myeloma.

General Oncology Genetic Predisposition to Cancer: Where Are We Now?

Genetic Predisposition to Cancer: Where Are We Now?

In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.

General Oncology Mobile Apps: The Future of Cancer Care?

Mobile Apps: The Future of Cancer Care?

From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.

General Oncology Spontaneous Regression of Cancer: Explanations and Predictions

Spontaneous Regression of Cancer: Explanations and Predictions

Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.

Multiple Myeloma Myeloma: Proteasome Inhibitors and IMiDs May Increase Risk of Cardiovascular Complications

Myeloma: Proteasome Inhibitors and IMiDs May Increase Risk of Cardiovascular Complications

Patients with underlying cardiovascular disease and/or baseline hypertension and coronary artery disease may be at a higher risk.

Multiple Myeloma Success of Adoptive Cell Therapy in ALL Could Be Applied to Myeloma

Success of Adoptive Cell Therapy in ALL Could Be Applied to Myeloma

In the treatment of myeloma, researchers are using therapies engineered to target a protein on myeloma cells called B cell maturation antigen.

Hematologic Cancers Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs

Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs

The high cost of CAR-T therapy concerns patient advocates who worry about the "financial toxicity" implications for patients and their families. But these cancer immunotherapies might offer an excellent value for clinical oncology, proponents claim.

General Oncology Establishing Links Between Germline Mutations and Oncogenesis

Establishing Links Between Germline Mutations and Oncogenesis

In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.

General Oncology Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.

Multiple Myeloma Paths Forward for Confronting Extramedullary Multiple Myeloma

Paths Forward for Confronting Extramedullary Multiple Myeloma

Extramedullary multiple myeloma is increasingly encountered in the clinic and most patients will need aggressive treatment.

Multiple Myeloma Virotherapy for Multiple Myeloma: The Current State of Research

Virotherapy for Multiple Myeloma: The Current State of Research

An emerging approach in the early stages of clinical development for MM is oncolytic virotherapy, in which viruses are used to eliminate cancer cells directly or indirectly.

Multiple Myeloma Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection

Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection

Clinicians can use a geriatric assessment for an objective appraisal of the health status of older patients with multiple myeloma.

Multiple Myeloma Q&A With Kristian Thidemann Andersen, MD, PhD: Infection in Multiple Myeloma After HDT-ASCT

Q&A With Kristian Thidemann Andersen, MD, PhD: Infection in Multiple Myeloma After HDT-ASCT

Cancer Therapy Advisor asked Dr Andersen about whether it is possible to improve outcomes among patients with multiple myeloma by identifying those at risk of infection among the transplant-eligible.

Multiple Myeloma Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths

Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths

Does the failure of pembrolizumab in multiple myeloma clinical trials imply checkpoint inhibition is unlikely to work for patients with the disease?

General Oncology Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.

General Oncology Malware in Medicine: Prevention Is Key to Protection

Malware in Medicine: Prevention Is Key to Protection

The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.

General Oncology Drug-herb and Drug-drug Interactions in Oncology

Drug-herb and Drug-drug Interactions in Oncology

Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.

General Oncology Immune-mediated Hepatitis: Challenges in Management

Immune-mediated Hepatitis: Challenges in Management

The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.

General Oncology Can the FDA Curb Drug Prices for Cancer Treatment?

Can the FDA Curb Drug Prices for Cancer Treatment?

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

General Oncology Industry Payments to Physicians: Confronting Conflicts of Interest

Industry Payments to Physicians: Confronting Conflicts of Interest

Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.

General Oncology Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Many cancers in humans are weakly immunogenic — if immunogenic at all — and overcoming this inherent property of cancer cells will be critical for the future success of cancer immunology.

Multiple Myeloma Q&A With Dr Shaji Kumar: Ameliorating Bortezomib-induced Peripheral Neuropathy

Q&A With Dr Shaji Kumar: Ameliorating Bortezomib-induced Peripheral Neuropathy

Cancer Therapy Advisor asked Dr Kumar to discuss his team's investigation into a dexamethasone dosing schedule for reducing the rates of peripheral neuropathy.

General Oncology Dermatomyositis and Cancer Risk

Dermatomyositis and Cancer Risk

Treating physicians should watch for any suspicious signs of cancer after DM is diagnosed.

Multiple Myeloma Vaccines Targeting Multiple Myeloma Offer Promising Therapeutic Approach

Vaccines Targeting Multiple Myeloma Offer Promising Therapeutic Approach

Vaccines targeting multiple myeloma antigens offer a promising therapeutic approach by helping the immune system to fight off cancer cells.

General Oncology Researchers Look To Effectively Treat Patients With Cancer By Studying Exceptional Responders

Researchers Look To Effectively Treat Patients With Cancer By Studying Exceptional Responders

Researchers are interested in identifying "exceptional responders" to cancer medications to help highlight biomarkers that will identify patients likely to respond to treatment.

General Oncology Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?

General Oncology Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.

General Oncology Pediatric Cancer Researchers Look To Preserve Reproductive Potential of Survivors

Pediatric Cancer Researchers Look To Preserve Reproductive Potential of Survivors

While survival rates of pediatric patients with cancer are greatly improved, researchers and clinicians are evaluating how to best preserve the reproductive potential of survivors.

Multiple Myeloma Multiple Myeloma Drug Resistance: New Immunotherapies May Improve Survival

Multiple Myeloma Drug Resistance: New Immunotherapies May Improve Survival

Increasing genetic complexity over time allows multiple myeloma to acquire drug resistance, but immunotherapies that overcome this hurdle might improve overall survival.

General Oncology Q&A With Scott Roberts, PhD: Direct-to-Consumer Cancer Gene Testing

Q&A With Scott Roberts, PhD: Direct-to-Consumer Cancer Gene Testing

In this question-and-answer session, Cancer Therapy Advisor asked Dr Roberts about direct-to-consumer genomic testing for cancer risk.

General Oncology Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.

Multiple Myeloma Q&A With Tanya Wildes, MD: Managing Multiple Myeloma in Older Patients

Q&A With Tanya Wildes, MD: Managing Multiple Myeloma in Older Patients

In this question-and-answer session, Cancer Therapy Advisor asked Dr Wildes about the management of multiple myeloma among older patients.

General Oncology Random Mutations May Be Leading Cause of Oncogenesis

Random Mutations May Be Leading Cause of Oncogenesis

According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.

General Oncology Proposed US Budget Cuts: Effects on Cancer Research

Proposed US Budget Cuts: Effects on Cancer Research

According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs